{"product_id":"biolegend-504120","title":"Biolegend, 504120, Brilliant Violet 421™ anti-mouse IL-4 Antibody, 500microl","description":"\u003cp\u003eIL-4 is a pleiotropic cytokine produced by activated T cells, mast cells, and basophils. IL-4 is a potent lymphoid cell growth factor which stimulates the growth and activation of certain B cells and T cells. IL-4 is important for regulation of T helper subset development.\u003cbr\u003e\n500microl\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: Partially purified native mouse IL-4\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.\u003cbr\u003e\nConcentration: µg sizes: 0.2 mg\/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: ICFC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450\/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.\u003cbr\u003e\nExcitation Laser: Violet Laser (405 nm)\u003cbr\u003e\nApplication Notes: ELISA1,2,10,13 or ELISPOT5 Capture: The purified 11B11 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated BVD6-24G2 antibody (Cat. No. 504202) as the detecting antibody and recombinant mouse IL-4 (Cat. No. 575609) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture.Neutralization1-2,9,12: The 11B11 antibody can neutralize the bioactivity of natural or recombinant IL-4. The LEAF™ purified antibody (Endotoxin \u0026lt;0.1 EU\/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IL-4 bioactivity in vivo and in vitro (Cat. No. 504108).Additional reported applications (for the relevant formats) include: immunoprecipitation16, immunohistochemical staining of formalin-fixed paraffin-embedded tissue sections8 and paraformaldehyde-fixed, saponin-treated frozen tissue sections6,7, and immunocytochemistry4.Note: For testing mouse IL-4 in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 431101 to 431106) are specially developed and recommended.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Shirai A, et al. 1994. Cytokine 6:329. (ELISA, Neut) Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20. (ELISA, Neut) Assenmacher M, et al. 1994. Eur. J. Immunol. 24:1097. Openshaw P, et al. 1995. J. Exp. Med. 182:1357. (ICC) Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19. (ELISA Capture) Litton M, et al. 1994. J. Immunol. Methods 175:47. (IHC) Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. (IHC) Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC) Hara M, et al. 2001. J. Immunol. 166:3789. (Neut) Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA) Lawson BR, et al. 2007. J. Immunol. 178:5366. Wang W, et al. 2007. J. Immunol. 178:4885. (Neut) Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed Ohnmacht C, et al. 2008. Blood 113:2816. PubMed Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Zavorotinskaya T, et al. 2003. Mol. Ther. 7:155. (IP)\u003cbr\u003e\nProduct Citations: Komuczki J, et al. 2019. Immunity. 50:1289. PubMed Vono M, et al. 2020. Cell Reports. 28(7):1773-1784.e5.. PubMed Chen R, et al. 2022. J Mol Cell Biol. 14:. PubMed Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed Zhang W, et al. 2022. Front Cell Dev Biol. 10:842813. PubMed Fang D, et al. 2022. Immunity. 55:639. PubMed Mikami Y, et al. 2021. Immunity. 54(3):514-525.e6. PubMed Wilfahrt D, et al. 2021. Elife. 10:. PubMed Shi B, et al. 2018. J Immunol. 200:586. PubMed Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed Yang J, et al. 2020. Nature. 586:572. PubMed Lou Y, et al. 2021. Int J Mol Sci. 22:. PubMed He C, et al. 2022. Nat Commun. 13:5459. PubMed Wang S, et al. 2022. J Inflamm Res. 14:7107. PubMed Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed\u003cbr\u003e\nRRID: AB_10896945 (BioLegend Cat. No. 504119) AB_2562594 (BioLegend Cat. No. 504127) AB_2562102 (BioLegend Cat. No. 504120)\u003cbr\u003e\nStructure: Cytokine; 15-19 kD (Mammalian)\u003cbr\u003e\nBioactivity: Differentiation of naïve CD4+ T cells to the TH2 type, proliferation\/differentiation of activated B cells, expression of class II MHC antigens, and of low affinity IgE receptors in resting B cells\u003cbr\u003e\nCell Sources: Mast cells, T cells, bone marrow stromal cells\u003cbr\u003e\nCell Targets: B cells, T cells, monocytes, endothelial cells, fibroblasts\u003cbr\u003e\nReceptors: Heterodimer IL-4Rα (CD124); γ-subunit (CD132) in common with IL-2R, IL-7R, IL-13R, IL-15R\u003cbr\u003e\nCell Type: Tregs\u003cbr\u003e\nBiology Area: Immunology\u003cbr\u003e\nMolecular Family: Cytokines\/Chemokines\u003cbr\u003e\nAntigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego. 2. Boulay J, et al. 1992. Curr. Opin. Immunol. 4:294. 3. Dullens H, et al. 1991. In vivo 5:567. 4. Paul W. 1991. Blood 77:1859.\u003cbr\u003e\nRegulation: Upregulated by IL-2, platelet activating factor; downregulated by TGF-β\u003cbr\u003e\nGene ID: 16189\u003cbr\u003e\nUniProt: View information about IL-4 on UniProt.org\u003cbr\u003e\nClone: 11B11\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: Interleukin-4, Ia inducing factor (IaIF), B cell stimulating factor-1 (BSF-1), Hodgkin's cell growth factor (HCGF), Mast cell growth factor-2 (MCGF-2), Macrophage fusion factor (MFF), T cell growth factor-2 (TCGF-2)\u003cbr\u003e\nIsotype: Rat IgG1, κ\u003cbr\u003e\nQ: What is the F\/P ratio range of our BV421™ format antibody reagents?\u003cbr\u003e\nA: It is lot-specific. On average it ranges between 2-4.\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46860791382185,"sku":"504120","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/biolegend-504120","provider":"Iright","version":"1.0","type":"link"}